Morningstar

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer ...

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on ...
VentureBeat

Preclinical Data on Circle Pharma’s CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the ...
VentureBeat

Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycle therapies, today announced that it presented a digital poster at the 2024 ...